Tuesday, May 30, 2017
 
 
Company News: Page (1) of 1 - 03/06/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Notes into shares

(March 06, 2017)

FIT Biotech Oy

Company release March 6, 2017 at 10:00 am

Conversion of FIT Biotech Oy's Convertible Notes into shares

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's board of directors has today resolved to approve Bracknor's request relating to the funding programme to convert EUR 40,000 worth of Convertible Notes into the Company's K shares.


Due to the conversion of the Convertible Notes, the Company issues 588,971 new K shares in the Company to Bracknor with the conversion price of EUR 0.067915 per share.

As a result of the issue of the new K shares in the Company, the total number of shares in the Company will increase to 50,198,328 shares, and the share capital of the Company will be increased by EUR 39,999.97. After the issue of the new K shares in the Company, the Company's shares will be divided in share series as follows: 50,127,864 K shares, 5,229 A shares and 65,235 D shares.

The increase of the share capital and new K shares in the Company will be registered in the Trade Register on or about March 7, 2017 and the new K shares will be admitted to trading on First North Finland on or about March 9, 2017.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTUŽ (Gene Transport Unit) vector technology for new-generation medical treatments. GTUŽ is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTUŽ technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Tutorial Finder ,   Review Seeker ,   Review Seeker ,   DMN Newswire Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • Silver Birch of Hammond Affordable Assisted Lifestyle Community Opens Doors
  • Global Blood Banking and Blood Products - Laboratory Equipment and Supplies
  • Male Infertility Market Size Worth $4.7 Billion by 2025 | CAGR: 4.6%: Grand View Research, Inc.
  • Dental Radiology and Dental Imaging Devices market is expected to grow with CAGR of approximately 10%
  • NetDirector Enables Next-Generation Integration in Radiology with American Health Imaging

    Cancer
  • Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
  • Global Endometrial Cancer Therapeutics Market to Reach $27 Billion by 2021 - Rising Global Endometrial Cancer Epidemics - Research and Markets
  • Global Rice Bran Oil Market Size, Share, Price, Trends and Growth Rate From 2017 To 2022 | Expert Market Research
  • Cone beam computed tomography (CBCT) Systems Market Expected to Reach $1,041 Million, Globally, by 2023 - Allied Market Research
  • Mesothelioma Compensation Center Now Urges the Family of a Person Who Recently Died From Mesothelioma Before They Could Hire a Lawyer to File a Claim to Call for Instant Help
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines